Literature DB >> 18793673

Development of the 1st International Reference Panel for HIV-1 RNA genotypes for use in nucleic acid-based techniques.

Harvey Holmes1, Clare Davis, Alan Heath.   

Abstract

Twenty-eight laboratories from 16 countries participated in a collaborative study to evaluate an HIV-1 RNA Genotype Reference Panel for use with nucleic acid-based tests (NAT). The Reference Panel consisted of 11 coded samples representing different HIV-1 genotypes (subtypes A-D, AE, F, G, AA-GH, groups N and O) as well as a negative diluent control. Each laboratory assayed the eleven panel members concurrently with the 1st International Standard for HIV-1 RNA (NIBSC Code 97/656) on at least three separate occasions and the data collated and analysed at NIBSC. Twenty-nine sets of data from NAT were received, 19 from quantitative and 10 from qualitative assays, with six different commercial assays and five "in-house" assays represented. The results showed that viruses from subtypes A-D and recombinant virus AE [CRF01_AE] were detected consistently, but that some assays had difficulty with the detection and quantification of viruses from subtypes F and G, a mixed recombinant virus AA-GH and a representative of group N. Furthermore, most assays failed to detect the group O representative. The study illustrated the limitations of some molecular assays particularly in detection of certain non-B genotypes which are important viruses in the global AIDS pandemic and illustrated the value of a well-characterised genotype panel. The panel has been established by the World Health Organisation's Expert Committee on Biological Standardisation as the 1st International Reference Panel HIV-1 RNA Genotypes (code 01/466).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18793673     DOI: 10.1016/j.jviromet.2008.08.014

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  7 in total

Review 1.  Standardization of Nucleic Acid Tests: the Approach of the World Health Organization.

Authors:  S A Baylis; P Wallace; E McCulloch; H G M Niesters; C M Nübling
Journal:  J Clin Microbiol       Date:  2019-01-02       Impact factor: 5.948

2.  Universal amplification, next-generation sequencing, and assembly of HIV-1 genomes.

Authors:  Astrid Gall; Bridget Ferns; Clare Morris; Simon Watson; Matthew Cotten; Mark Robinson; Neil Berry; Deenan Pillay; Paul Kellam
Journal:  J Clin Microbiol       Date:  2012-09-19       Impact factor: 5.948

3.  Human Immunodeficiency Virus (HIV).

Authors: 
Journal:  Transfus Med Hemother       Date:  2016-05-09       Impact factor: 3.747

4.  Performance evaluation of the new Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test version 2.0 for quantification of human immunodeficiency virus type 1 RNA.

Authors:  Suzan Pas; John W A Rossen; Daniel Schoener; Diana Thamke; Annika Pettersson; Reiner Babiel; Martin Schutten
Journal:  J Clin Microbiol       Date:  2010-02-17       Impact factor: 5.948

Review 5.  Standardization of NAT for Blood-Borne Pathogens.

Authors:  Sally A Baylis; Michael Chudy; C Micha Nübling
Journal:  Transfus Med Hemother       Date:  2015-07-01       Impact factor: 3.747

6.  Generation of a recombinant Gag virus-like-particle panel for the evaluation of p24 antigen detection by diagnostic HIV tests.

Authors:  Beatrice N Vetter; Vanessa Orlowski; Katrien Fransen; Christoph Niederhauser; Vincent Aubert; Marcel Brandenberger; Diana Ciardo; Günter Dollenmaier; Thomas Klimkait; Stephan Regenass; Patrick Schmid; Volkmar Schottstedt; Franziska Suter-Riniker; Sabine Yerly; Cyril Shah; Jürg Böni; Jörg Schüpbach
Journal:  PLoS One       Date:  2014-10-24       Impact factor: 3.240

7.  A novel diagnostic target in the hepatitis C virus genome.

Authors:  Jan Felix Drexler; Bernd Kupfer; Nadine Petersen; Rejane Maria Tommasini Grotto; Silvia Maria Corvino Rodrigues; Klaus Grywna; Marcus Panning; Augustina Annan; Giovanni Faria Silva; Jill Douglas; Evelyn S C Koay; Heidi Smuts; Eduardo M Netto; Peter Simmonds; Maria Inês de Moura Campos Pardini; W Kurt Roth; Christian Drosten
Journal:  PLoS Med       Date:  2009-02-10       Impact factor: 11.069

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.